1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пер. с англ. М.: Атмосфера, 2007.
2. Tashkin DP, Celli B, Senn S et al. for the UPLIFT Study Investigators. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New Engl J Med 2008; 359: 1543–54.
3. www.aarc.org/resources/confronting_copd/exesum.pdf
4. Аверьянов А.В., Чучалин А.Г., Поливанова А.Э и др. Фенотипы больных хронической обструктивной болезнью легких Тер. арх. 2009; 81 (3): 9–15.
5. Valderramas S, Atallah N. Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: A Randomized Trial. Resp Care. March 2009; 54 (3): 327–33.
6. Homnick D. Mechanical Insufflation-Exsufflation for Airway Mucus Clearance. Respir Care 2007; 52 (10): 1296–307.
7. Rubin B. Designing clinical trials to evaluate mucus clearance therapy. Respir Care 2007; 52 (10): 1348–58.
8. Rubin B. Mucolytics, Expectorants, and Mucokinetic Medications Respir Care 2007; 52 (7): 859–65.
9. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
10. Ripoll L, Reinert P, Pe´pin LF, Lagrange PH. Interaction of macrolides with alpha (sic) dornase during DNA hydrolysis. J Antimicrob Chemother 1996; 37 (5): 987–91.
11. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109 (2): 348–52.
12. Kuhn JJ, Hendley JO, Adams KF et al. Antitussive effect of guaifenesin in young adults with natural colds. Chest 1982; 82: 713–8.
13. Elkins MR, Robinson M, Rose BR et al. National Hypertonic Saline in Cystic Fibrosis (NHSCF)Study Group. A controlled trial of long-term inhaled hypertonicsaline in patients with cystic fibrosis. N Engl J Med 2006; 354 (3): 229–40.
14. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirol 2005; 10 (1): 46–56.
15. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. J Appl Physiol 1985; 58 (6): 1776–82.
16. Frohock JI, Wijkstrom-Frei C, Salathe M. Effects of albuterol en antiomers on ciliary beat frequency in ovine tracheal epithelial cells. J Appl Physiol 2002; 92 (6): 2396–402.
17. Daviskas E, Anderson SD, Eberl S et al. Effects of terbutaline in combination with mannitol on mucociliary clearance. Eur Respir J 2002; 20 (6): 1423–9.
18. Weich DJ, Viljoen H, Sweetlove MA et al. Investigation into the effect of Fenoterol onmucociliary clearance in patients with chronic bronchitis. Eur J Nucl Med 1988; 14 (11): 533–7.
19. Isawa T, Teshima T, Hirano T et al Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs. Tohoku J Exp Med 1986; 150 (1): 51–61.
20. Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance J Allergy Clin Immunol 2002; 110 (6, Suppl.): S291–7.
21. Anzueto A, Jubran A, Ohar JA et al. Effects of aerosolized surfactant in patients with stable chronicbronchitis: a prospective randomized controlled trial. J Am MedAssoc 1997; 278 (17): 1426–31.
22. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331 (10): 637–42.
23. Ramsey BW, Astley SJ, Aitken ML et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148 (1): 145–51.
24. Puchelle E, Zahm JM, de Bentzmann S et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996; 9 (4): 765–9.
25. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (5): 795–8.
26. Boman G, Backer U, Larsson S et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64 (6): 405–15.
27. Rogers DF. Mucoactive Agents for Airway Mucus Hypersecretory Diseases Respiratory Care 2007; 52 (9): 1176–97.
28. Havez R, Degand P, Roussel P et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon Coeur 1977; 26: 81–90.
29. Ischiura Y, Fujimura M, Yamamori C et al. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol 2003; 55: 504–10.
30. Edwards GF, Steel AK, Scott JK, Jordan JW. S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 1976; 70: 506–13.
31. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629): 2013–8.
32. Dorow P, Weiss T, Felix R, Schmutzler H. Effect of a secretolytic and a combination of pinene, limonene and cineole on mucociliary clearance in patients with chronic obstructive pulmonary disease Arzneimittelforschung 1987; 37 (12): 1378–81.
33. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92 (4): 618–20.
34. Ericsson CH, Juhaa^sz J, Joe`nsson E, Mossberg B. Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function. Eur J Respir Dis 1986; 69: 248–55.